Current treatment and future prospects for peripheral T-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Peripheral T-cell lymphoma (PTCL) encompasses rare, aggressive subtypes with unique characteristics.
• PTCL often presents with extranodal involvement, B symptoms, and paraneoplastic phenomena, leading to a poor 5-year survival rate of approximately 30%.

Purpose of the Study:

• To review the distinct tumor biology of PTCL subtypes.
• To discuss current and emerging targeted therapies and treatment options for PTCL.
• To emphasize the critical need for collaborative, randomized controlled trials in PTCL management.

Main Methods:

• Literature review of PTCL pathogenesis, clinical presentation, and treatment strategies.
• Analysis of current therapeutic approaches, including first-line treatments and stem cell transplantation.
• Evaluation of novel agents in early-phase trials for relapsed/refractory PTCL.

Main Results:

• PTCL subtypes exhibit diverse biological behaviors and clinical presentations.
• Treatment resistance and high relapse rates contribute to poor patient outcomes.
• Stem cell transplantation plays a role in both first-line and relapsed settings.

Conclusions:

• Understanding the specific biology of PTCL subtypes is crucial for effective treatment.
• Advancements in targeted therapies and novel agents offer new hope for relapsed/refractory disease.
• Collaborative clinical trials are essential to improve outcomes for this aggressive group of lymphomas.